Abstract: microRNAs (miRNAs) are short (~ 22 nucleotides), non-coding, single-stranded RNA molecules that regulate the expression of target genes by partial sequencespecific base-pairing to the targeted mRNA 3′UTR, blocking its translation, and promoting its degradation or its sequestration into processing bodies. miRNAs are important regulators of several physiological processes including developmental and metabolic functions, but their concentration in circulation has also been reported to be altered in many pathological conditions such as familial hypercholesterolemia, cardiovascular diseases, obesity, type 2 diabetes, and cancers. In this review, we focus on the role of miRNAs in lipoprotein and lipid metabolism, with special attention to the well-characterized miR-33a/b, and on the huge potential of miRNAs for clinical application as biomarkers and therapeutics in the context of cardiometabolic diseases.
Introduction
Since their first discovery in worms in 1993 [1] , microRNAs (miRNAs) have been described as important regulators of several biological processes from cellular differentiation and development to metabolic function regulation, and their deregulation in diseased states has repeatedly been reported. The role of miRNAs as central regulators of lipoprotein metabolism and cholesterol homeostasis is now well established in the literature (reviewed in [2] [3] [4] [5] ). However, the role of lipoprotein-bounded miRNAs as endocrine regulators has recently emerged. Although studies on lipoprotein-transported miRNAs suggest distinct miRNA profiles in the two major lipoproteins found in circulation, the data support that miRNAs have a stronger role in high-density lipoprotein (HDL) than in low-density lipoprotein (LDL) in regulating their metabolic functions [6] [7] [8] . The discovery of miRNAs transported by lipoproteins thus opens up the way for two main clinical applications: biomarkers of diseases and targeted therapies. In this review, we describe the basics of miRNA biology and focus on the important role of miRNAs in lipoprotein and lipid metabolism. We also describe where potential clinical applications currently stand and discuss future research perspectives and their challenges.
miRNA biogenesis and biological function
miRNAs are evolutionarily-conserved short [~ 22 nucleotides (nt)], non-coding, single-stranded RNAs involved in the post-transcriptional regulation of potentially > 60% of the human genes [9] . The miRNAs biogenesis pathway is detailed in Figure 1 . Briefly, miRNAs are encoded in the genome and are transcribed, mostly by the RNA polymerase II, as a ~ 1000-nt capped and polyadenylated primary miRNA (pri-miRNA) from their own promoter (intergenic) or from co-expression with their host protein-coding gene (intragenic) [10] . The pri-miRNA is then cleaved by the microprocessor complex (Drosha/DGCR8) to generate a 70-nt hairpin-structured precursor miRNA (pre-miRNA), which is exported to the cytoplasm by the Exportin5-RanGTP system [10] . The pre-miRNA is subjected to a second cleavage by the Dicer/TRBP complex, releasing a ~ 22 nt miRNA duplex (miRNA-3p/miRNA-5p) [10] . The miRNA duplex is subsequently loaded onto an Argonaute protein (AGO1-4, in humans), by an ATP-dependent mechanism involving the heat shock cognate 70 (HSC70)-heat shock protein 90 (HSP90) chaperone complex, to form the pre-RNA-induced silencing complex (RISC) [10] . Based on the relative thermodynamic stability of the two miRNA strands, the one with the weakest binding at its 5′ end is more likely to become the strand (guide) selected to form the mature RISC complex, while the other strand (passenger) is quickly removed and degraded [10, 11] . This selection, however, is flexible depending on cell types, developmental stages and disease states [11] . This means that either the miRNA-3p or the miRNA-5p may be selected to form the mature RISC complex (reviewed in [11] ).
The biological function of miRNAs is usually, but not exclusively, attributed to the repression of protein synthesis through their (mostly partial) base-pairing to the 3′ untranslated region (UTR) of their mRNA target, which is mainly dependent of the complementarity at nucleotides 2-8 of the miRNA (i.e. miRNA seed region; at the 5′-end of the miRNA), although the nucleotides 13-16 also contribute to mRNA targeting specificity (i.e. miRNA 3′ supplementary site) [12] . This interaction consequently inhibits mRNA translation and promotes mRNA sequestration into processing bodies as well as its degradation (mRNA destabilization and decay, accelerated by mRNA deadenylation and decapping; Figure 1 ), the latter producing greater repressive effect at steady state [10, [13] [14] [15] . These miRNA-mediated gene-silencing mechanisms have been reviewed in [15] and [16] . However, it has been shown that miRNAs could bind functional sites in the 5′UTR as well as in the protein-coding region of mRNAs, promoting gene translation in certain circumstances [17] [18] [19] . While a single miRNA may target several (often, but not always, functionally related) genes, a single mRNA may harbor many binding sites for the same or different miRNAs [20] . Moreover, two miRNA-binding sites closely located on a miRNA genes (intragenic or intergenic) are transcribed, mostly by the RNA polymerase II (Pol II), as a primary miRNA (pri-miRNA) [10] . The pri-miRNA is cleaved the microprocessor complex (Drosha/DGCR8) to generate a hairpin-structured precursor miRNA (pre-miRNA) which is then exported to the cytoplasm by the Exportin5-RanGTP system [10] . The pre-miRNA is subjected to a second cleavage by the Dicer/TRBP complex, releasing a ~ 22 nt miRNA duplex (miRNA-3p/miRNA-5p), which is then loaded onto an Argonaute protein (AGO1-4, in humans) to form the pre-RNA-induced silencing complex (RISC) [10] . Based on relative thermodynamic stability of the ends of the two miRNA strands, one strand (guide) is selected to form the mature RISC complex, while the other strand (passenger) is quickly removed and degraded [10] . Non-canonical miRNA biogenesis pathways [e.g. bypassing the processing by either Drosha (e.g. mirtrons) or Dicer (e.g. miR-451)] have also been characterized for a few specific miRNAs (reviewed in [10] ). Through (mostly partial) base-pairing to the 3′ UTR of its target mRNA, miRNA regulates the expression of target genes by repressing mRNA translation and promoting mRNA sequestration into processing bodies as well as mRNA destabilization and degradation (mRNA decay, accelerated by mRNA deadenylation and decapping) [10] .
mRNA could act synergistically to post-transcriptionally regulate gene expression [21] . Although the central role of miRNAs is to negatively regulate protein synthesis, other functions of miRNAs are emerging (reviewed in [22] and [23] ). Particularly, miRNAs have been found to regulate the stability of nuclear transcripts (e.g. mRNAs, long non-coding RNAs (lncRNAs) or pri-miRNAs), induce epigenetic alterations at specific gene promoters, and likely modulate alternative splicing events in the nuclear compartment [22] [23] [24] [25] [26] . Moreover, two studies have reported few specific miRNAs as ligands for toll-like receptor (TLRs; TLR7 in mice and TLR8 in humans) activation [27, 28] . Overall, miRNAs are important gene expression regulators that, cooperatively and at various steps of the gene expression process, orchestrate the fine-tuning of gene expression at diverse development stages, for different cell types and disease states [20] .
miRNA expression regulation and stability
The steady-state concentration of mature miRNAs in cells depends on their tightly regulated transcription, maturation, and decay (reviewed in [10] and [29] ). It has been proposed that approximately ≈ 100 copies of a mature miRNA per cell is required for biologically relevant repression of gene translation [30, 31] . The regulation of the miRNA concentration therefore plays an important part in the control of the miRNA regulatory function. Briefly, miRNA transcription is regulated by specific transcription factors and epigenetic marks (e.g. DNA methylation, histone modifications) [13] . Like protein-coding genes, certain miRNAs display a tissue-specific expression pattern [32] , supporting their roles in cellular differentiation and development [33] . Moreover, the miRNA-processing efficiency is regulated through various post-translational modifications of the maturation machinery (Drosha, DGCR8, Dicer, TRBP, AGO) [10, 13] . Also, the miRNA itself is subjected to post-transcriptional modifications such as RNA editing, methylation, uridylation and adenylation [13] . These modifications, in addition with protein complex formation (e.g. AGO) and exposure to nucleases [e.g. 5′-3′ exoribonuclease 2 (XRN-2)], modulate the miRNA stability and decay [29] .
miRNAs show high stability (> 24 h) in cells and plasma, with miRNA persistence varying from one miRNA to another [34] [35] [36] [37] . Interestingly, miRNAs have also been found in virtually all biological fluids, including cerebrospinal fluid, tears, saliva, breast milk, amniotic fluid, urine, as well as feces [38] [39] [40] [41] [42] 
Role of miRNAs in lipoprotein and lipid metabolism miRNAs as regulators of lipid metabolism and function
Cholesterol is an essential molecule for animal cell physiology. It is involved in the regulation of the plasma membrane fluidity and integrity, as well as in membrane protein functionality (e.g. cell signaling, intracellular transport). It is the precursor for steroid hormones, bile acids, and vitamin D biosynthesis [44, 45] . As altered cholesterol levels have been repeatedly associated with cardiometabolic diseases (e.g. atherosclerosis), a strict regulation of the lipoprotein metabolism ( Figure 2 ; reviewed in [62] ) is essential to maintain cholesterol homeostasis and thus health. Since their discovery [1] , miRNAs have been proposed as important regulators of metabolism homeostasis in humans [63] [64] [65] . The number of miRNAs with validated target genes involved in lipid and lipoprotein metabolism has increased significantly in the last decade ( Figure 2 and Table 1 ). So far, the best characterized miRNA that regulates lipid and lipoprotein metabolism is miR-33a/b.
miR-33a/b
The miR-33 family member miR-33a is evolutionarily conserved across animal species, whereas miR-33b is conserved only in certain mammals [81, 127] . In humans, miR-33a and miR-33b are encoded within intronic regions of the sterol regulatory element-binding transcription factor (SREBF) genes SREBF2 and SREBF1, respectively [82] . SREBFs encode key membrane-bound transcription factors involved in the activation of numerous genes implicated in biosynthesis and uptake of cholesterol and in the synthesis of fatty acids [e.g. 3-hydroxy-3-methyglutaryl-CoA reductase (HMGCR), low-density lipoprotein receptor (LDLR), fatty acid synthase (FASN), stearoyl-CoA desaturase (SCD), and acetyl-CoA carboxylase alpha (ACACA)] [128, 129] . Under low intracellular cholesterol levels, MIR33A is transcribed concomitantly with SREBF2 and increases the cholesterol biosynthesis and uptake (SREBP2) as well as reduces cholesterol efflux and excretion (miR-33a) [83, 128, 130] . Alternatively, MIR33B is cotranscribed with SREBF1 under insulin and liver x receptor (LXRs) activation [5] , promoting fatty acid synthesis (SREBP1), repressing fatty acid oxidation, and increasing intracellular cholesterol levels (miR-33b) [83, 128, 130] . Several studies performed using miRNA mimics/inhibitors in cultured cells and animal models have suggested an important role of miR-33a/b in HDL and lipid metabolism regulation (Table 1 ; reviewed in [130] and [2] ). miR-33a/b have been shown to regulate cholesterol efflux by targeting the cholesterol transporter gene ABCA1 in human hepatocytes and human and mice macrophages, and to regulate ABCG1 in mice macrophages [84, 127] . miR-33a/b [44, 46] . Lipoproteins present diverse sizes (7-1200 nm of diameter) and can be classified based on their respective density or electrophoretic mobility [47] . The exogenous lipoprotein pathway, which comprises the apoB48-containing lipoproteins, consists in dietary lipid transport from the intestine to energy-demanding tissues such as muscle, adipose tissue and the liver [46, [48] [49] [50] [51] [52] [53] . The endogenous lipoprotein pathway, which comprises the apoB100-containing lipoproteins, allows the transport of lipids from the liver to peripheral tissues [46, [49] [50] [51] [52] [53] [54] [55] . The reverse cholesterol pathway consists in the efflux of excess cholesterol from extrahepatic tissues to HDLs and its transport to the liver for metabolization and excretion into the bile in the intestine [56] [57] [58] [59] [60] . Importantly, circulating lipoproteins undergo constant remodeling by interacting with various partners (e.g. LCAT, CETP, PLTP, HL, LPL), which implicates cargo exchanges between different lipoproteins (reviewed in [57] and [61] ). All these pathways are well described with more details in the references mentioned above. Several miRNAs with validated target genes (*) involved in these lipoprotein metabolism pathways (in blue) have been identified so far (detailed in have been found to target other genes associated with cholesterol metabolism, including the Niemann-Pick disease type C1 (NPC1) [84] , cholesterol 7α-hydroxylase (CYP7A1), ATPase aminophospholipid transporter class 1 type 8B member 1 (ATP8B1), and ATP-binding cassette subfamily B member 11 (ABCB11) genes [85, 86] . In addition to their role in cholesterol metabolism homeostasis, miR-33a/b have been found to regulate the cellular fatty acid metabolism by repressing many genes contributing to fatty acid oxidation in hepatocytes [e.g. carnitine palmitoyltransferase 1A (CPT1a), carnitine O-octanoyltransferase(CROT)] [83, 87] and to regulate insulin signaling by targeting the insulin receptor substrate 2 (IRS2) and sirtuin 6 (SIRT6) genes [83] . Finally, the in vivo administration of miR-33a/b inhibitor oligonucleotides in mice and non-human primates has sustainably raised plasma HDL-C levels and decreased very low-density lipoprotein (VLDL)-associated triglyceride levels [81, 82, 84, 88, 89] , two factors associated with the metabolic syndrome [131] . Overall, miR33a/b are important regulators of metabolic homeostasis, including cholesterol, lipid and glucose/insulin metabolism and represent a potential novel therapeutic target in atherosclerosis and the metabolic syndrome [88, 89] .
miRNAs carried by lipoproteins High-density lipoprotein HDL-carried miRNA concentration is altered in diseased state
HDLs exert their anti-atherogenic action primarily through their important role in promoting the reverse cholesterol transport [56] , but they also mediate several other less well-characterized cardioprotective functions, such as anti-inflammatory, antioxidant, anti-thrombotic, anti-apoptotic, and insulin-secretagogue actions [132] . HDLs comprise an heterogeneous population of particles in terms of both structure and functionality (reviewed in [132] ). Indeed, HDLs are composed of a large variety of proteins (> 80), lipid species (> 200), and miRNAs [6, 133] . The pioneering work of Vickers et al. first suggested that HDLs transport and deliver functional miRNAs to recipient cells with gene regulation capabilities [6] . Interestingly, the HDL-carried miRNA profile was considered biologically distinct from the one observed in purified LDLs and exosomes, these latter being more closely related to each other [6] . One of the most abundant and best characterized miRNAs carried by HDLs is miR-223-3p [6, 7, 134] . HDL-transported miR-223-3p concentrations have been reported to be significantly increased in participants with homozygous familial hypercholesterolemia (FH) [135] , and in athero-prone mice [Apolipoprotein E (ApoE) −/− or LDLR −/− mouse models on high-fat diet (HFD)] (Table 2) [6] . Moreover, hypercholesterolemia has also been associated with increased hepatic cholesterol and miR-223-3p levels in ApoE −/− mice on HFD, suggesting that liver miR-223-3p expression is associated with cholesterol levels in vivo [119] . Accordingly, miR-223-3p concentration in cultured human hepatocytes and mice macrophages was found positively associated with intracellular cholesterol concentrations, and the MIR223 promoter activity was demonstrated to be cholesterol-sensitive (downregulated in low-cholesterol state) [119] . Importantly, miR-223-3p was found to target several genes involved in the cholesterol metabolism. At high intracellular cholesterol levels, miR-223-3p is upregulated and represses cholesterol biosynthesis [targeting the 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) and methylsterol monooxygenase 1 (SC4MOL) mRNAs] as well as HDL-C uptake [targeting the scavenger receptor class B type I (SR-BI) mRNA], and indirectly enhances ABCA1-mediated cholesterol efflux to HDLs [targeting the transcription factor SP3 (SP3) mRNA] [119] . Under low intracellular cholesterol levels, miR-223-3p expression is downregulated and its targets repression is relieved; increasing cholesterol biosynthesis and uptake [119] . Consequently, miR-223-3p appears as an The miR-33a/b binding site in the 3′UTR of ABCG1 gene is present in rodents, but is not conserved in humans. important mediator of intracellular and systemic cholesterol homeostasis. Other HDL-carried miRNAs have been associated with hypercholesterolemia, inflammation, and acute coronary syndrome (ACS) when compared to healthy subjects (Table 2 ) [6, 7] .
Wagner et al. were the first to assess the contribution of HDL-carried miRNAs to the total plasmatic miRNA pool [7] . The percentages of HDL-bound miRNAs related to those detected in plasma associated to other carriers were found to be relatively low (< 1% to ~ 8%) in healthy subjects, with HDL-carried miR-223-3p contributing the most to the plasmatic pool of circulating miRNAs (~ 8%) [7] . A contribution level varying from one miRNA to another suggests that over the relatively large variety of plasmatic miRNAs carried by HDLs, a specific subset of plasmatic miRNAs might be enriched in HDLs. These miRNAs would be of particular biological relevance, potentially contributing to HDL functionality (e.g. miR-223-3p, which is abundantly transported in HDLs and have regulatory functions in cholesterol metabolism [119] and in inflammation [136] ).
Very recently, Niculescu et al. showed that miR-486-5p and miR-92a-3p were upregulated in the serum of patients with CAD [including stable angina (SA), unstable angina (UA) and myocardial infarction (MI)] compared to healthy subjects ( Table 2 ), and that these differences were also found significant in the HDL 2 and HDL 3 subpopulations [8] . Most importantly, the authors concluded that these differences in HDL-carried miR-486-5p and miR-92a-3p concentrations may discriminate between stable and vulnerable CAD patients [8] . Interestingly, miR-92a-3p has been identified as one of the most concentrated miRNAs in HDLs by Wagner et al. [7] . However, miR-92a-3p was not preferentially associated to HDLs relatively to other plasmatic carriers (~ 2% contribution to the plasmatic miRNA pool) [7] . This miRNA might well remain an excellent biomarker of CAD, but our enthusiasm is diminished regarding its specific role in the regulation of the many HDL functions.
HDL-carried miRNA concentration is affected by the diet
More recently, studies from our and other groups tested whether HDL-transported miRNA concentrations were sensitive to diet-induced metabolic changes. Tabet et al. showed a mild decrease in HDL-carried miR-223-3p concentration following a 12-week diet rich in proteins and that this change in HDL-miR-223-3p level was associated with a diet-induced weight loss in overweight and obese men (Table 3 ) [137] . Our group reported an increased concentration of HDL-carried miR-223-3p and miR-135a-3p, which was associated with an overall worsening of the cardiovascular disease (CVD) risk profile (e.g. lowered HDL-C and increased high-sensitivity C-reactive protein (hsCRP) and TG concentrations; Table 3 ) following a 4-week double-blinded, randomized, crossover, controlled dietary intervention rich in trans fatty acids (TFA) from industrial (iTFA) or ruminant (rTFA) sources [134] .
miRNA transfer to HDLs
The HDL-carried miRNA profile is distinct but also shares similarities with that of plasma, LDLs, and (to a lesser extent) exosomes [6, 7] . This was expected considering that HDLs are an integral part of plasma (like other carriers), that a complex interplay exists between different lipoprotein pathways, and that circulating miRNAs (independently of the carrier) may be of common cellular origin ApoA1, apolipoprotein A1; iTFA, trans fatty acids from industrial source; rTFA, trans fatty acids from ruminants. a Obese and overweight men followed either a diet rich in proteins (HP; 30% daily energy; n = 20) or a control diet with normal protein amount (NP; 20% daily energy; n = 27), for 12 weeks. Relatively to pre-diet baseline, mean HDL-carried miR-223-3p concentration was lowered (~ -1.3-folds) following the HP diet only, and this change in HDL-miR-223-3p level was associated with diet-induced weight loss.
b Following a double-blind, randomized, crossover, controlled design, nine healthy men were fed each of the three isoenergetic diets for 4 weeks each, with a washout period of ≥ 3 weeks between diets: (1) rich in iTFA (3.7% daily energy); (2) rich in rTFA (3.7% daily energy); (3) low in TFAs (control; 0.8% daily energy). The variations in HDL-carried miR-223-3p and miR-135a-3p concentration following a diet rich in TFAs compared to the control diet were strongly correlated with diet-induced changes in cardiometabolic risk markers.
(e.g. hepatocytes, macrophages, endothelial cells). Nevertheless, certain miRNAs (e.g. miR-223-3p) were more importantly transported by HDLs in plasma [7] , suggesting that a subset of miRNAs might potentially be more specifically (actively) loaded in HDLs rather than in other carriers. This process could be supported by either cell type-specificity of membrane transporters and miRNA expression or post-transcriptional modifications of miRNAs that would increase their affinity for HDLs.
The exact mechanism by which miRNAs are transferred to HDLs and delivered to recipient cells is still poorly described [138] . An obvious transporter is ABCA1, since it mediates the cholesterol and phospholipid efflux to lipid-poor ApoA1 [84] , but its overexpression in cultured mice macrophage resulted only in a modest increase in miR-223-3p levels (1.8-folds) in reconstituted HDLs (rHDL) [6] . Interestingly, sphingomyelin (SM) binds RNA and prevents its degradation by RNAses [139, 140] . Moreover, a few groups have reported that small RNAs could bind to phospholipid membranes using vesicular models [141] [142] [143] [144] . Whether the plasma membrane SM, enriched into lipid rafts, could also bind miRNA and contribute to its export to HDLs has not been published so far. However, the chemical inhibition of the neutral sphingomyelinase 2 (nSMase2; the rate-limiting enzyme in ceramide biosynthesis from SM) was shown to reduce the cellular miRNA export by exosomes [145] [146] [147] . Using inhibition of the nSMase2 in cultured mice macrophage, Vickers et al. reported that the miR-223-3p export to rHDLs was significantly increased (35-folds), suggesting distinct and possibly opposing mechanisms for miRNA export to HDLs and exosomes through the SM-ceramide pathway [6] . This pathway may nevertheless constitute an important regulatory mechanism that will have to be further explored.
Delivery of functional HDL-carried miRNAs to recipient cells
Circulating miRNAs have been suggested to play a role in endocrine-like intercellular communication [6, 148] . The first evidence of HDL-carried miRNA biological functionality was provided in 2011 by Vickers et al. [6] . As a proof of concept, the authors showed that native HDLs loaded with miR-375 or miR-223-3p miRNA mimics efficiently delivered these miRNAs to cultured human hepatocytes, with a concomitant decrease in mRNA levels of two putative target genes of miR-223-3p [6] . Moreover, the miRNA transfer to recipient cells was demonstrated to be mostly SR-BIdependent [6] . Importantly, Vickers' group demonstrated that Huh7 cells treated with HDLs from FH patients (abnormally abundant in miR-105-5p) showed increased intracellular miR-105-5p levels, whereas no change was observed when cells were incubated with HDLs from healthy patients [6] . Interestingly, 60% of the concomitantly downregulated mRNAs in Huh7 cells treated with HDLs from FH subjects harbored a putative target site of miR-105-5p [6] . This work proposed for the first time that endogenous HDL-carried miRNAs may be transferred to recipient cells with functional capabilities, although the possible contribution of other constituents of HDLs to the observed transcriptomic changes in cultures hepatocytes could not be excluded.
In a more recent publication, the same group elegantly demonstrated that native HDL efficiently transfers miR-223-3p to human coronary artery endothelial cells (HCAEC), into which miR-223-3p was not naturally transcribed nor processed [136] . Importantly, Tabet et al. showed that change in intracellular miR-223-3p levels following incubation with HDLs was transcription-independent in cells pretreated with actinomycin D, suggesting that this change in miR-223-3p levels might likely be due to HDL miRNA transfer to the cell [136] . Moreover, they demonstrated that HDL-transferred miR-223-3p efficiently repressed ICAM-1 using luciferase assays [136] . This suggested for the first time that HDL-carried miR-223-3p likely contribute to the atheroprotective HDL anti-inflammatory action in endothelial cells, by limiting monocyte adhesion to endothelial cells [136] . This is concordant with the previously identified anti-inflammatory function of miR-223-3p in macrophages [149] .
Another group has measured the HDL-carried miRNA transfer to human umbilical venous endothelial cells (HUVEC), vascular smooth muscle cells (SMC) and peripheral blood mononuclear cells (PBMC) [7] . The authors first showed that HDL-introduced exogenous Caenorhabditis elegans (cel)-miR-39 can be transferred to HUVECs, but in low levels only (< 10 copies/cell) [7] . This group did not show a significant miRNA transfer from native HDLs to HUVECs, SMCs and PBMCs, but reported a slight decrease in intracellular miR-223-3p, miR-92a-3p and miR-126-3p levels, especially in the PBMCs [7] . This was observed after a relatively short incubation with native HDLs from healthy subjects [7] . Interestingly, the intracellular miRNA levels were decreased in PBMCs after incubation with HDLs from healthy subjects, whereas they were increased after incubation with HDLs from CAD and ACS patients [7] . This differential cellular response to HDLs from healthy and diseased subjects may reflect physiological changes in HDL functions [150] . The analysis of intracellular pri-miRNA and pre-miRNA levels revealed that the observed changes in PBMCs might be due to transcriptional changes in miR-126-3p, but not miR-223-3p and miR92a-3p [7] , raising the interesting hypothesis that PBMCs may export miRNAs to HDLs. The direction of the miRNA exchange between HDL and cells (import or export) could possibly be influenced by cell culture conditions and contribute to explain, at least partially, the observed discrepancies between these studies.
Although the transfer (and possibly exchange) of functional HDL-carried miRNAs to recipient cells has been demonstrated in different cultured cells [6, 7, 119] , the HDL's capacity to deliver (exchange) functional miRNAs in vivo has not been investigated so far. This matter will be of major importance in the future.
Low-density lipoprotein and other ApoB-containing lipoproteins
As for HDLs, IDL and LDL particles were also found to transport miRNAs in circulation [6] [7] [8] . Despite the recognized implication of LDLs in atherosclerosis development and the strong association between high LDL-C levels and increased risk of CVDs [4] , the LDLs' miRNA cargo has been less studied than that of HDLs. Initial work from Vickers et al. allowed the identification of several miRNAs particularly abundant in LDLs including, among others, miR-223-3p, miR-150-5p, miR-19b-3p, miR-24-3p, miR-92a-3p and miR-146a-5p [6] . From the nine miRNAs quantified by Wagner's group, miR-223-3p was also reported as the most concentrated in LDLs from healthy subjects [7] . Moreover, miR-92a-3p has been repeatedly identified as one of the most abundant miRNA carried by LDLs and IDLs [6] [7] [8] .
Although most miRNAs found by Wagner et al. in LDLs and IDLs from healthy subjects were more abundant in HDLs [7, 8] , which may partially explain the greater enthusiasm toward the HDL-carried miRNA transport as compared to LDLs, Wagner's group identified one miRNA, miR-155-5p, that was more concentrated in LDLs than in HDLs [7] . miR-155-5p is implicated in the regulation of various physiological processes including hematopoiesis, immunity, inflammation and adipogenesis. Its overexpression has been previously associated with several inflammation-related pathologies such as cancers, atherosclerosis, CVD and obesity [151] [152] [153] [154] . miR-155-5p plays a central role in the regulation of macrophage polarization toward the M1 pro-inflammatory phenotype, and was found to play a role in the atherogenic programming of macrophages by indirectly upregulating the monocyte chemotactic protein 1 (MCP1), a chemokine known to promote monocyte recruitment to the atherosclerotic plaque and thus vascular inflammation [152] . Noteworthy, the miR-155-5p concentration in macrophages was found to be increased in presence of native and mildly oxidized LDLs, whereas profoundly oxidized LDLs lowered the miR-155-5p concentration in macrophages [152] . Although the functional potential of LDL-carried miRNAs has not been investigated yet, this observation may suggest a possible transfer of LDL-carried miR-155-5p to macrophages or, alternatively, a change in cellular miR-155-5p expression induced by LDLs, which is likely affected by the degree of LDL oxidation [7] . Taken together, these pioneering studies suggest that LDL-and IDL-carried miRNA profiles may be altered in the diseased state, and more particularly in CAD (Table 2) , and support the assessment of the role of these lipoproteins miRNAs profiles in larger studies [7, 8] .
Biomarkers miRNA as potential biomarkers of CVDs
Due to their gene regulatory function in diverse biological processes and metabolic functions [63] [64] [65] 155] , as well as their high stability in biological fluids [34] [35] [36] [37] , circulating miRNAs have been pointed out as an exciting avenue for the identification of new, non-invasive biomarkers of diseases. Compared with the usual protein biomarkers, miRNAs could provide early disease markers (there usually needs to be tissue damage for protein biomarkers to be liberated) or greater specificity. Indeed, miRNAs can be detected quantitatively by the real-time quantitative polymerase chain reaction (RT-qPCR) technique with high sensitivity, specificity and multiplexing potential [43, 156] . However, RT-qPCR remains a relatively timeconsuming technique compared to many analyses currently used in clinical laboratories, and no consensus on a data normalization method is currently established (see Kappel et al. in this special edition for details on miRNA detection) [156, 157] . Also, the amount of miRNA in easily accessible biological matrixes (e.g. plasma, urine) is generally small, making a reliable miRNA quantification and results reproducibility more difficult [156, 157] . Some miRNAs are modulated in more than one pathology, limiting the specificity and thus the applicability of these miRNAs as biomarkers [156] .
Despite these challenges, several studies have investigated the potential usefulness of miRNAs based on reported differences in miRNA signature in health and disease [43, 156, 157] . To date, most of the literature in the field focuses on cancers and CVDs [158] [159] [160] . Numerous reviews describe miRNAs as potential biomarkers for CVDs, individually or in a panel signature, for single or mixed use (diagnostic, prognostic, and staging) [159, 161] . Some studies have compared these miRNAs to the current reference biomarkers such as troponin (I and T) [159, 161] . Interestingly, Zampetaki et al. challenged the use of miRNAs as predicators of cardiovascular events and showed that circulating miR-126, miR-197 and miR-223 are strongly associated with the risk of future MI, and that adding the circulating levels of these three miRNAs to the usual Framingham risk score (FRS) improves by ~ 15% the risk classification [162] . This improvement is better than that observed when adding the hsCRP levels to the risk score calculation [163] , supporting the high potential of circulating miRNAs.
Lipoprotein-bound miRNAs as a biomarker
Lipoproteins are widely used as biomarkers in the evaluation of the CVD risk. Although these biomarkers are mainly based on lipoprotein-cholesterol levels, more recent studies suggested that the lipoprotein characteristics (e.g. composition, functionality) were more strongly associated to the CVD risk than solely its cholesterol content [164] [165] [166] [167] [168] . The discovery that miRNAs are transported by lipoproteins opens up our minds to new possibilities [6] . Although many plasmatic miRNAs have been identified as potential CVD biomarkers, most of them have not been correlated yet with established CVD biomarkers [161] . An interesting hypothesis would be that the carrier-specific miRNA signature is a more accurate biomarker of a disease state than that of plasma. The association of the specific HDL-carried miRNA profile with various diseases and metabolic status (Tables 2 and 3) , as well as these miRNAs' biological relevance illustrate the potential of HDL-transported miRNAs as biomarkers (and therapeutics; see next section). No study has yet evaluated the clinical benefits of HDL-associated miRNAs over that of standard biomarkers. As reported above, Niculescu et al. have showed that among the six miRNAs upregulated in plasma from CAD compared to healthy subjects, miR-486-5p and miR-92a-3p could discriminate between CAD stages in regard to their levels in HDLs [8] . MiR-486-5p has been identified in various cancer studies [169] , and its serum concentration has been reported negatively correlated with systemic ventricular contractility following a cardiac bypass surgery [170] . More importantly, miR-486-5p has been associated with the angiogenesis process and was recently shown to regulate the cholesterol efflux from macrophages [171, 172] . Literature about the association of miR-92a-3p and its related cluster with CVD is much more abundant and generally agrees with Niculescu's study [173, 174] . Very interestingly, miR-92a-3p has been identified as an atheromiR in a large scale screen in human umbilical vein endothelial cells (HUVECs) searching for upregulated miRNAs in response to the presence of oxidized LDL and low shear stress [175] . This could help in refining the CAD status prediction (see Zeller et al. in this special edition for more details on miRNAs in CVD).
The use of circulating miRNAs in a non-invasive screening, diagnostic or prognostic of disease is an exciting and awaited clinical application of miRNAs. Based on the current knowledge, plasmatic and lipoprotein-associated miRNAs (individually or as a set of related miRNAs) have great potential to become clinically used biomarkers in the future. However, larger well-designed studies with standardized methodologies (e.g. sampling, miRNA extraction and quantification techniques, data normalization method) are needed to achieve this important goal.
Therapy
Nowadays, statins are one of the most prescribed classes of drugs to treat dyslipidemia and for the prevention and management of CVDs [176] . Statins decrease the de novo cholesterol synthesis through HMGCR inhibition, and lower the cholesterol levels in plasma through indirect upregulation of LDLR via SREBP2 activation (in response to decreasing cellular cholesterol levels) [176] [177] [178] [179] . Up to now, statins have been the only lipid lowering drug conferring a significant (~ 25%) reduction of the risk of CVD [176] [177] [178] . Others lipid lowering drugs, such as fibrates [180, 181] , niacin [178] and ezetimibe [178] , are also available, but their effects on CVD risk prevention are limited (alone or in combination with statins). Numerous others molecules are currently in development targeting various lipoprotein biosynthesis steps, including inhibitors of ApoB biosynthesis, MTP activity, and ApoC-III synthesis, as well as the very promising proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors [178, 182, 183] . In contrast, the HDL-raising therapies developed over the past years, including over-expression of APOA1 gene, infusion of reconstituted HDL particles or recombinant lecithin-cholesterol acyltransferase (LCAT) and CETP inhibitors [178, 184] , have failed to prevent CVD occurrence despite a huge increase (up to 180%) in HDL levels [177, 178, [185] [186] [187] . This clearly shows that the HDL particle is much more complex than previously thought. Accordingly, our understanding of different HDL functions and the molecular mechanisms involved needs to be refined.
To this end, novel classes of molecules are currently in development, targeting HDLs' metabolism, particle structure and function [178, 185] . One such class is miRNAs, which have emerged as potential candidates because they are important regulators of lipid metabolism and can target several mRNAs implicated in a given pathway. As for conventional drugs, the development of a miRNA-based drug is a challenging multi-step process (recently reviewed in [188] and [189] ). It begins with the profiling of miRNAs in health and disease states [188] . Either downregulated or upregulated miRNAs (i.e. biologically relevant in disease development or progression) are then selected and tested in vitro and in vivo for gain and loss of function [188] . Since miRNA levels may be either increased or decreased, two classes of miRNA-based treatments have been described [188] [189] [190] . miRNA antagonists, also known as antagomiR or anti-miR, are antisense oligonucleotides which complementary bind to the targeted mature miRNA, causing its loss of function by creating a duplex unable to bind its target mRNA and inhibit its translation [189] . Since free-synthetic and exogenous miRNAs are rapidly degraded in biological fluids, these antagomiRs need to be structurally stabilized in order to increase their half-life and cellular uptake [189] . The antagomiR structural stabilization can be achieved by the incorporation of 2′-O-methyl modified oligonucleotides as well as locked nucleic acid (LNA) modified nucleotides or by modifying linkages between nucleotides [191, 192] . Also, adding a cholesterol molecule to the original antagomiR structure has already been used to increase its cellular uptake (more specifically in the cardiac tissue) [191] . Another strategy to downregulate a miRNA function is the use of miRNA sponges, which harbor multiple complementary sites to the targeted miRNA [193] .
Furthermore, the levels of miRNAs downregulated in disease may be normalized using miRNA mimics, which are synthetic double-stranded oligonucleotides that mimic the miRNA function they replace [188, 189] . Similar to antagomiRs, miRNA mimics are chemically modified to improve their stability and cellular uptake [188] . However, only the "passenger strand" is usually modified, while the "guide strand" remains identical to the mature miRNA of interest [189] . Alternatively, the expression of a downregulated target miRNA may be stably normalized by the use of adenovirus-associated vectors and tissue-specific promoters [194] .
Various methods of miRNA-based treatment delivery have been described [188] . It is clear that the specific delivery of the molecule to a particular site of action is still a challenge, but one that needs to be addressed in order to limit the undesirable side-effects of the treatment [32] . Pharmacodynamics is also difficult to assess since miRNAs regulate numerous genes and pathways and the summation of these effects requires sophisticated analytical models. Anti-miR and miR-mimetic treatments may induce toxicity related to the chemical structure of the molecule and also toxicity related to the hybridization potential of the molecule to other undesirable target mRNAs (off-target) or tissue.
Even though a good number of miRNAs have been described in the literature in various pathologies and are candidates to become potential miRNA-based treatments, only a few are now under serious development [188, 189] . Two miRNA mimics (miR-34 and let-7) targeting oncogenes implicated in the development of solid tumors are presently in preclinical development [195] . miRNA antagonists are also of interest, with candidates under development: three miRNAs (miR-195 et miR-208/499) in preclinical targeting CVD and one miRNA (miR-122) in phase II clinical trial targeting hepatitis C viral infection [196, 197] . Importantly, a miR-33 antagonist is currently under preclinical development [129, 189] . As reported above, miR-33 is central in cholesterol homeostasis, and its inhibition raises HDL-C levels, increases the cholesterol reverse transport from macrophages and is atheroprotective. Other miRNAs are also good candidates for the treatment of dyslipidemias, including miR-30c-5p and miR-148a-3p. The overexpression of miR-30c-5p has been showed to reduce plaque formation in an atherosclerotic mouse model and, alternatively, its inhibition has induced hyperlipidemia and increased atherosclerotic plaque formation [80] . The action of miR-30c-5p was mediated by the inhibition of MTP, which regulates the secretion of VLDL by the liver, even though miR-30c-5p can also mediate its action in a MTP-independent way. miR-148a-3p is also an interesting target for a miRNA-based treatment, because this miRNA has been found to downregulate two genes important in lipoprotein metabolism: LDLR and ABCA1 [115] . The expression of miR-148a-3p was increased in the liver of high-fat diet mice and rhesus monkeys [105] , and its inhibition in huh7 cells and mice models was shown to significantly increase hepatic LDLR and ABCA1 expression, concomitant with increased HDL-C and decreased LDL-C levels in circulation [105, 115] . Moreover, miR148a-3p was also able to repress ABCA1 and the cholesterol efflux capacity in mice macrophages [105] . Also, a large genome-wide association study (GWAS) meta-analysis (> 188,000 individuals) identified two polymorphisms within the MIR148a promoter region that were associated with plasma levels of total cholesterol, LDL-C and triglycerides, suggesting that this miRNA is involved in lipid homeostasis in humans [105] . These miRNAs have been linked to the lipid metabolism and atherosclerosis and are thus very promising novel therapeutic targets.
The demonstration that HDLs could transport a specific and metabolically sensitive set of functional miRNAs and deliver them to recipient cells led us to an endocrinelike signaling pathway which still needs to be validated in vivo [6] . This discovery could improve our understanding of the functionality of HDLs in cardioprotection. It could support the interesting possibility of using HDL particles to deliver specific miRNA therapies. Infusion of synthetic HDL particles is presently in phase II trial [184] . These particles are composed of ApoA1 and phospholipids, mimicking nascent HDLs. Loading these synthetic HDLs with functional miRNAs is an exciting avenue to improve HDL-directed therapy, by which HDLs could stabilize and deliver functional antagonist or mimetic miRNAs.
Conclusions
The involvement of miRNAs as central regulators of the lipoprotein metabolism and cholesterol homeostasis is now well established. The role of lipoprotein-carried miRNAs as functional regulators or useful biomarkers is emerging. HDLs have been shown to transport and deliver functional and metabolically-sensitive miRNAs to recipient cells in vitro (e.g. hepatocytes and endothelial cells), raising the interesting hypothesis of an endocrinelike intercellular communication mediated by HDLs (and possibly other lipoproteins). This may contribute to mediate the HDL-cardioprotective functions. Despite the enthusiasm raised by the lipoprotein (mostly HDLs)-carried miRNAs and the increasing number of publications in this area, the current lack of data still limits our understanding of the biological relevance and functions of these miRNAs in vivo. More studies are needed to elucidate the molecular mechanism by which miRNAs are exchanged between lipoproteins and cells (e.g. cellular origin and destination, miRNA ligand, receptors, specificity), as well as their functional impact in intercellular communication in vivo. Moreover, the physiological relevance of the plasmatic miRNAs preferential location (e.g. HDLs, LDLs, exosomes, RNA-binding proteins) in regard to cardiometabolic homeostasis has also not been determined yet. Larger studies will also be necessary to fully investigate the biomarker (refinement) and therapeutic potential of lipoprotein-carried miRNAs in diseases. In conclusion, lipoprotein transport of miRNAs is an exciting research avenue to explore in regard of lipoprotein functionality and potential miRNA-based clinical applications for the prevention and treatment of cardiometabolic diseases.
